ONCT - Oncternal Therapeutics, Inc.
IEX Last Trade
0.5477
-1.162 -212.215%
Share volume: 0
Last Updated: Mon 02 Dec 2024 09:06:57 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.71
0.00
0.00%
Fundamental analysis
24%
Profitability
25%
Dept financing
4%
Liquidity
75%
Performance
15%
Performance
5 Days
0 0%
1 Month
-29.79%
3 Months
-63.68%
6 Months
-93.16%
1 Year
-95.54%
2 Year
-97.27%
Key data
Stock price
$0.55
DAY RANGE
$0.64 - $1.71
52 WEEK RANGE
$0.70 - $11.45
52 WEEK CHANGE
-$94.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: James B. Breitmeyer
Region: US
Website: oncternal.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: oncternal.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Oncternal Therapeutics, Inc. focuses on the development of oncology therapies for cancers with critical unmet medical needs. Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1)
Recent news